Key statistics
As of last trade XOMA Royalty Corp (0M26:LSE) traded at 30.00, -8.74% below its 52-week high of 32.87, set on Nov 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 30.00 |
Low | 30.00 |
Bid | -- |
Offer | -- |
Previous close | 0.00 |
Average volume | 49.00 |
---|---|
Shares outstanding | 11.78m |
Free float | 11.68m |
P/E (TTM) | -- |
Market cap | 354.31m USD |
EPS (TTM) | -3.06 USD |
Data delayed at least 20 minutes, as of Nov 22 2024 14:30 GMT.
More ▼
- XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
- XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
- Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
- XOMA Royalty Declares Quarterly Preferred Stock Dividends
- XOMA Royalty to Present at Upcoming Investor Conferences in September
- XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
- XOMA Declares Quarterly Preferred Stock Dividends
- XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
- XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
- XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
More ▼